Skip to main content
Vivoryon Therapeutics N.V. logo

Vivoryon Therapeutics N.V. — Investor Relations & Filings

Ticker · VVY ISIN · NL00150002Q7 LEI · 3912004AMB0KGZXZYJ15 AS Manufacturing
Open in API
Filings indexed 400 across all filing types
Latest filing 2026-04-23 Earnings Release
Country NL Netherlands
Listing AS VVY

About Vivoryon Therapeutics N.V.

https://www.vivoryon.com/

Vivoryon Therapeutics N.V. is a clinical-stage precision medicine company focused on developing first-in-class therapies by targeting post-translational modifications of proteins. The company's scientific approach centers on inhibiting glutaminyl cyclases (QPCT and QPCTL), enzymes that catalyze pyroglutamate formation, a process implicated in the progression of various diseases. Its lead product candidate, varoglutamstat, is an orally administered small molecule QPCT/L inhibitor. Vivoryon is advancing its therapeutic pipeline for patients with inflammatory, fibrotic, and neurodegenerative diseases, with a strategic focus on conditions such as chronic kidney disease.

Recent filings

Filing Released Lang Actions
Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update
Earnings Release Classification · 90% confidence The document is a press release titled “Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update” with bullet‐point highlights, CEO quotes, summary financial metrics, outlook, and invitation to a conference call. It is an initial announcement of annual results rather than the full annual report, fitting the definition of an Earnings Release (ER). FY 2025
2026-04-23 English
Vivoryon Therapeutics N.V., Jaarlijkse financiële verslaggeving
Annual Report Classification · 100% confidence The document is explicitly titled 'Vivoryon Therapeutics N.V. Annual Report 2025'. It contains comprehensive sections including a report by executive members, financial review, risk management, corporate governance, and full financial statements (statements of operations, financial position, cash flows, and notes). It covers the full fiscal year ending December 31, 2025, and meets all criteria for a formal annual report. FY 2025
2026-04-23 English
Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026
Report Publication Announcement Classification · 85% confidence The document is a short press release (approx. 4.5k characters) announcing the date and logistics for the company’s full year 2025 financial results release and conference call, and stating that the report will be available on the website. There are no actual financial results or highlights disclosed. Under the “menu vs meal” rule, this is an announcement of the timing and publication of a report, not the report itself, so it falls under Report Publication Announcement (RPA).
2026-04-15 English
Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference
Regulatory Filings Classification · 75% confidence The document is a standard press release announcing the company’s management participation at an upcoming investor conference. It does not contain financial results, an actual investor presentation, or any report attached; it merely informs stakeholders of a conference attendance. There is no detailed presentation content (so not IP), report publication (so not RPA), or other specific event filings. Thus, it falls under a general regulatory announcement category (RNS).
2026-04-09 English
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
Regulatory Filings Classification · 68% confidence The document is a corporate press release announcing scientific data presentations at the World Congress of Nephrology. It does not present financial results (so not an Earnings Release or Interim/Annual Report), nor is it a formal investor slide deck (so not Investor Presentation), nor does it involve governance, M&A, financing, dividends, or share transactions. It is a general regulatory announcement updating the market on clinical trial data. Hence it falls into the fallback category of Regulatory Filings (RNS).
2026-03-30 English
VeonGen Announces Clinical Progress of VG801 Gene Therapy in Stargardt Disease, with an Oral Presentation at ARVO 2026
Regulatory Filings Classification · 88% confidence The document is a corporate press release announcing clinical progress of a gene therapy and an upcoming oral presentation. It does not contain financial results, regulatory form disclosures (e.g., 10-K, IR, ER), management changes, capital structure updates, or voting information. It is a generic corporate news announcement, fitting the fallback “Regulatory Filings” category (RNS).
2026-03-25 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.